InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
6
Disclosed sells
0
T+90 hit rate
25%
T+90 mean return
+1.2%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by SCHIMMEL PAUL, Director. Director active across 2 companies, notably aTYR PHARMA INC. Aggregated, 8 disclosures have been logged. Breakdown: 6 buys · 0 sell. Total volume traded: €4.2m. Activity tracked since 18 May 2021. The latest transaction was disclosed on 22 July 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
41,052 shares@ US$1.74172.6% of flowCommon StockSEC:0000950170-24-086159:0
Ideal exit: 18 Apr 2025 (T+270)
200,000 shares@ US$2.2516.3% of flowCommon StockSEC:0001209191-23-028607:0
Ideal exit: 4 Feb 2024 (T+270)
6,000 sharesCommon stockSEC:0001209191-23-026067:0
250,000 shares@ US$8.002.22% mcap84.0% of flowCommon StockSEC:0001209191-21-057339:0
Ideal exit: 17 Jun 2022 (T+270)
250,000 shares@ US$8.00100.0% of flowCommon StockSEC:0001209191-21-057339
Ideal exit: 17 Jun 2022 (T+270)
50,000 shares@ US$3.988.0% of flowCommon StockSEC:0001209191-21-034293
Ideal exit: 12 Feb 2022 (T+270)
50,000 shares@ US$3.980.21% mcap8.0% of flowCommon StockSEC:0001209191-21-034293:0
Ideal exit: 12 Feb 2022 (T+270)
11,925 sharesCommon StockSEC:0001209191-16-094247:0
8 of 8 declarations
About SCHIMMEL PAUL
Paul Schimmel is a Board Member at aTYR Pharma Inc. He plays a key role in the governance of the company, contributing to strategic decision-making and overseeing operations. His experience in the pharmaceutical sector allows him to provide valuable insights to the board.
